Molecular pathways and therapeutic targets in lung cancer

Emma Shtivelman, Thomas Hensing, George R. Simon, Phillip A. Dennis, Gregory A. Otterson, Raphael Bueno, Ravi Salgia

Research output: Contribution to journalArticle

Abstract

Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.

Original languageEnglish (US)
Pages (from-to)1392-1433
Number of pages42
JournalOncotarget
Volume5
Issue number6
DOIs
StatePublished - 2014

Keywords

  • Immune therapy
  • Lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Molecular pathways and therapeutic targets in lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014). Molecular pathways and therapeutic targets in lung cancer. Oncotarget, 5(6), 1392-1433. https://doi.org/10.18632/oncotarget.1891